



Article Palladium Iodide Catalyzed Multicomponent Carbonylative Synthesis of 2-(4-Acylfuran-2-yl)acetamides

Ida Ziccarelli¹, Lucia Veltri^{1,*}, Tommaso Prestia¹, Roberta Amuso¹, Maria A. Chiacchio², Raffaella Mancuso¹ and Bartolo Gabriele^{1,*}

- ¹ Laboratory of Industrial and Synthetic Organic Chemistry (LISOC), Department of Chemistry and Chemical Technologies, University of Calabria, Via Pietro Bucci 12/C, 87036 Arcavacata di Rende, Italy; ida.ziccarelli@unical.it (I.Z.); tommaso.prestia@gmail.com (T.P.); roberta.amuso@unical.it (R.A.); raffaella.mancuso@unical.it (R.M.)
- ² Department of Drug Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy; ma.chiacchio@unict.it
- * Correspondence: lucia.veltri@unical.it (L.V.); bartolo.gabriele@unical.it (B.G.); Tel.: +39-0984-492817 (L.V.); +39-0984-492815 (B.G.)

Abstract: 2-Propargyl-1,3-dicarbonyl compounds have been carbonylated under oxidative conditions and with the catalysis of the PdI_2/KI catalytic system to selectively afford previously unreported 2-(4acylfuran-2-yl)acetamides in fair to good yields (54–81%) over 19 examples. The process takes place under relatively mild conditions and occurs via a mechanistic pathway involving *Csp*-H activation by oxidative monoamincarbonylation of the terminal triple bond of the substrates with formation of 2-ynamide intermediates, followed by 5-*exo-dig O*-cyclization (via intramolecular conjugate addition of the in situ formed enolate to the 2-ynamide moiety) and aromative isomerization.

Keywords: alkynes; amides; aminocarbonylation; carbonylation; C–H activation; conjugate addition; cyclization; furans; oxidative carbonylation; palladium

1. Introduction

Functionalized furans are a very important class of heterocyclic derivatives [1], known to possess important biological activities (see, for example, references [2,3]) and being useful precursors for further transformations (for a review, see reference [4]).

Among the synthetic methods available to prepare multisubstituted furans (for recent reviews, see references [5–7]), transition metal-catalyzed cyclization (TMCC) of suitable acyclic precursors is particularly attractive (for recent reviews, see references [8,9]; for a book, see reference [10]; for a recent example, see reference [11]). By this approach, the final compound with the desired substitution pattern can be obtained in one synthetic step starting from readily available substrates.

On the other hand, carbon monoxide is a very important C-1 building block in organic synthesis (for a recent book on carbonylation chemistry in organic synthesis, see reference [12]). In fact, CO can be installed in a large variety of organic substrates under different conditions, including transition-metal catalysis, to give high value–added carbonyl compounds (carbonylation reactions), including carbonylated heterocycles (for selected book chapters and reviews on metal-catalyzed carbonylation reactions, also leading to carbonylated heterocycles, see references [12–23]). Accordingly, the combination between TMCC and catalytic carbonylation with the appropriate acyclic precursor may represent an excellent entry to the direct synthesis of carbonyl-functionalized furan derivatives [12].

In particular, the catalytic system based on PdI_2 in conjunction with an excess of KI, developed by our research group [24,25] (for a recent review, see reference [26], has proved very valuable for the realization of several important carbonylative cyclization processes, particularly under oxidative conditions, with the one-step formation of carbonylated



Citation: Ziccarelli, I.; Veltri, L.; Prestia, T.; Amuso, R.; Chiacchio, M.A.; Mancuso, R.; Gabriele, B. Palladium Iodide Catalyzed Multicomponent Carbonylative Synthesis of 2-(4-Acylfuran-2-yl)acetamides. *Molecules* 2023, 28, 6764. https://doi.org/10.3390/ molecules28196764

Received: 31 August 2023 Revised: 15 September 2023 Accepted: 17 September 2023 Published: 22 September 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). heterocyclic derivatives. Among the different routes that the PdI_2/KI catalytic system is able to promote, the *Csp*-H activation by oxidative monoalkoxycarbonylation of the terminal triple bond, disclosed by our group in 2001 for the catalytic synthesis of 2-ynamides from simple alkyl- or arylacetylenes (Scheme 1a) [27,28], is particularly significant. In fact, this reactivity has been successfully employed for the synthesis of a plethora of heterocyclic derivatives, when applied to terminal alkyne substrates bearing a nucleophilic group in suitable position for the occurrence of an intramolecular conjugate addition to the initially formed 2-ynamide intermediate (Scheme 1b) (for a review, see reference [26]; for a very recent example, see reference [29]).



Scheme 1. PdI₂/KI-catalyzed oxidative monoaminocarbonylation of: (**a**) Simple alkyl- and arylacetylenes to give 2-ynamides [27,28] and (**b**) This work: 2-propargyl-1,3-dicarbonyl compounds **1** with amines **2** to 2-(4-acylfuran-2-yl)acetamides **3**.

In this work, we report a new application of this concept, which allows the direct, multicomponent synthesis of previously unreported 2-(4-acylfuran-2-yl)acetamides **3** starting from readily available 2-propargyl-1,3-dicarbonyl compounds **1**, carbon monoxide, and a secondary amine **2**. In this case, the initially formed 2-ynamide intermediate **I** (formed by **2**-promoted *Csp*-H palladation of **1** followed by CO insertion and nucleophilic displacement by **2**) undergoes 5-*exo-dig* intramolecular conjugate addition from the oxygen of enolate moiety resulting from C-2 deprotonation by the basic amine, to give intermediate **II**, whose aromative isomerization eventually leads to 2-(4-acylfuran-2-yl)acetamides **3** (Scheme 2). It is worth noting that, as seen in the reaction of simple alkyl- and arylacetylenes (Scheme 1a) [27,28], the method is not applicable to the use of primary amines, as these compounds preferentially undergo oxidative carbonylation to ureas under our reaction conditions [30,31]. Moreover, as already seen for simple 1-alkynes [27,28], secondary amines of relatively low nucleophilicity (such as alkylarylamines of diarylamines) are not sufficiently reactive to give the reaction.



Scheme 2. Mechanistic route leading to 2-(4-acylfuran-2-yl)acetamides **3** by PdI₂/KI-catalyzed oxidative aminocarbonylation of 2-propargyl-1,3-dicarbonyl compounds **1** with secondary amines **2** through the formation of 2-ynamide intermediates **I** and **II**.

This approach, therefore, allows the direct synthesis of a new subclass of furan derivatives (2-(4-acylfuran-2-yl)acetamides **3**) by the catalytic assembly of very simple building blocks (2-propargyl-1,3-dicarbonyl compounds **1**, amines **2**, CO, and O₂), with formation of water as benign coproduct.

2. Results and Discussion

We started our investigation using 3-(prop-2-yn-1-yl)pentane-2,4-dione **1a** as model substrate. The initial reaction was carried out in MeCN (0.10 mmol of **1a** per mL of MeCN) at 100 °C in the presence of PdI₂ (1 mol%), KI (KI:PdI₂ molar ratio = 100) and Et₂NH **2a** (3 equiv) under 20 atm (at 25 °C) of a 4:1 mixture CO-air. After 15 h, **1a** conversion was complete, and, after column chromatography purification, 2-(4-acetyl-5-methylfuran-2-yl)-N,N-diethylacetamide **3aa** was recovered in 61% yield (based on starting **1a**), in perfect agreement with our work hypothesis (Table 1, entry 1).

Table 1. PdI₂-catalyzed oxidative aminocarbonylation of 3-(prop-2-yn-1-yl)pentane-2,4-dione **1a** under different conditions ^a.

		Me Me 1a	+ CO + Et ₂ NH	+ (1/2)O ₂ Pdl ₂ / -H ₂ C		O NEt ₂ 3aa		
Entry	Solvent	KI (Equiv)	2a (Equiv)	Substrate Concn. ^b	T (°C)	P _{CO} (atm)	P _{air} (atm)	Yield of 3aa (%) ^c
1	MeCN	1	3	0.10	100	16	4	61
2	dioxane	1	3	0.10	100	16	4	56
3	DMA ^d	1	3	0.10	100	16	4	41
4	MeCN	0.5	3	0.10	100	16	4	45
5	MeCN	1	2	0.10	100	16	4	29
6	MeCN	1	4	0.10	100	16	4	68
7	MeCN	1	5	0.10	100	16	4	66
8	MeCN	1	3	0.20	100	16	4	63
9	MeCN	1	3	0.05	100	16	4	51
10	MeCN	1	3	0.10	100	32	8	53
11 ^e	MeCN	1	3	0.10	80	16	4	54
12	MeCN	1	4	0.20	100	16	4	72
13 ^f	MeCN	1	4	0.20	100	16	4	55

^a Unless otherwise noted, all reactions were carried out in 15 h, using 1 mol% of PdI₂. Substrate conversion was quantitative in all cases. ^b Mmol of starting **1a** per mL of solvent. ^c Isolated yield based on starting **1a**. ^d DMA = N_r -dimethylacetamide. ^e The GLC analysis showed the presence of trace of substrate. ^f The reaction was carried out using 0.33 mol% of PdI₂.

After a brief optimization study, in which we varied some reaction parameters (such as solvent, amount of KI and amine, substrate concentration, and total pressure; Table 1), a 72% isolated yield of **3aa** was achieved under conditions similar to those of the first experiment, but with a higher substrate concentration (0.22 mmol of **1a** per mL of MeCN) and using 4 equiv of Et₂NH **2a** (Table 2, entry 1). The reaction could also be performed with a lower catalyst loading (0.33 mol% PdI₂, maintaining the KI:PdI₂ molar ratio = 100), with an acceptable 55% isolated yield of **3aa** (Table 2, entry 2).

	R ¹ —	Pdl ₂ (0.33 ³ KI (33 or 1	or 1 mol%) 00 mol%) R ¹		
		R ₂ NH (2 ; CO (16 atm MeCN, 100	4 equiv)), air (4 atm) R ^{2~}) °C, 15 h		
Entry	PdI ₂ (mol%)	1	2	3	Yield of 3 (%) ^b
1	1	Me Me	Et₂NH 2a		72
2	0.33	1a	2a	3aa	55
3	1	1a	Me ₂ NH 2b	Me Me 3ab	67
4	0.33	1a	2b	3ab	55
5	1	1a	Bu₂NH 2c	Me O NBu ₂	75
6	0.33	1a	2c	3ac	58
7	1	1a	NHEt 2d	Me O Me O 3ad Et	74
8	0.33	1a	2d	3ad	59
9	1	1a	ⁱ Pr ₂ NH 2e	Me Me 3ae	54
10	1	1a	ONH 2f	Me Me 3af	74
11	0.33	1a	2f	3af	61
12	1		2a		81
13	0.33	1b	2a	3ba	68
14	1		2a		67
15	0.33	1c	2a	3ca	58
16	1	Me Me 1d	2f	Me Me Me 3df	66

Table 2. Synthesis of 2-(4-acylfuran-2-yl)acetamides 3 by PdI_2/KI -catalyzed oxidative aminocarbony-lation of 2-propargyl-1,3-dicarbonyl compounds 1 with secondary amines 2 a.

Table 2. Cont.

	R ¹	Pdl ₂ (0.33 c R ³ KI (33 or 1)	or 1 mol%) 00 mol%) F	0 R ¹ R ³ 0	
	$\mathbb{R}^2 \overline{\langle} 0$	R ₂ NH (2 ; CO (16 atm) 1 MeCN, 100	4 equiv) , air (4 atm) °C, 15 h	R ² NR ₂ 3	
Entry	PdI ₂ (mol%)	1	2	3	Yield of 3 (%) ^b
17	1	Ph- Ph- 1e	2a		68
18	0.33	1e	2a	3ea	62
19	1	Ph Ph Ph 1f	2a	Ph Ph O Ph O Ph O 3fa	54
20	1	Ph- Me- 1g	2f		48
				Me Ph 3gf	25
21	1	MeO Me 1h	2a	MeO Me 3ha	70
22	0.33	1h	2a	3ha O	58
23	1	Eto Me	2a		69
24	0.33	1i	2a	3ia	58
25	1	Eto	2a		68
26	0.33	1j	2a	3ja	63
27	1	Eto [/] Pr	2a		71
28	0.33	1k	2a	3ka	60
29	1	BnO Me	2a		67
30	0.33	11	2a	3la	56
31	1	Et ₂ N Me 1m	2a		57



^a All reactions were carried out in MeCN as the solvent (0.20 mmol of **1** per mL of MeCN), in the presence of PdI₂ (1 mol% or 0.33 mol%), KI (KI:PdI₂ molar ratio = 100), and amine **2** (4 equiv) for 15 h, under 20 atm of a 4:1 mixture of CO–air. Substrate conversion was quantitative in all cases. ^b Isolated yield based on starting **1**.

The reaction was then extended to other secondary amines **2b**–**f** (Table 2, entries 3–11) and different 2-propynyl-1,3-diketones **1b–g** (Table 2, entries 12–18). Similar results with respect to the parent reactions (Table 2, entries 1 and 2) were observed with other simple dialkylamines, such as Me₂NH 2b (Table 2, entries 3 and 4), Bu₂NH 2c (Table 2, entries 5 and 6), and even with sterically hindered N-ethylcyclohexylamine 2d (Table 2, entries 7 and 8). Interestingly, more sterically demanding diisopropylamine 2e was also reactive, and led to the formation of the corresponding furanacetamide **3ae** in 54% yield with 1 mol% catalyst (Table 2, entry 9). A cyclic amine like morpholine 2f reacted well and delivered the corresponding product 3af in either 74% yield (with 1 mol% PdI₂; Table 2, entry 10) or 61% yield (with 0.33 mol% catalyst; Table 2, entry 11). With Et₂NH 2a or morpholine 2f as the amine, extension of the protocol to other symmetrical 2-propargyl-1,3-diketones 1b-e also led to good results, the corresponding furans being obtained in 66–81% yields with 1 mol% catalyst (Table 2, entries 12, 14, 16, 17) and 58–68% yields with 0.33 mol% catalyst (Table 2, entries 13, 15, 18). Only in the presence of a phenyl group α to the triple bond, as in 1,3-diphenyl-2-(1-phenylprop-2-yn-1-yl)propane-1,3-dione 1f, a lower product yield was observed, probably for steric reasons (54%, Table 2, entry 19). Clearly, the use of an unsymmetrical diketonic substrate, such as 1-phenyl-2-(prop-2-yn-1-yl)butane-1,3-dione 1g, afforded a mixture of isomeric products 3gf and 3gf', which could be separated in 48% and 25% isolated yields, respectively (Table 2, entry 20). On the other hand, a selective process was observed with β -keto esters **1h–l**, owing to the higher nucleophilicity of the ketonic oxygen with respect to the estereal one [32], with selective formation of alkyl 5-(2-(dialkylamino)-2-oxoethyl)-2-alkylfuran-3-carboxylates (Table 2, entries 21–30). The method also worked nicely with 2-acetyl-N,N-diethylpent-4-ynamide 1m and 1-phenyl-2tosylpent-4-yn-1-one 1n, with formation of 5-(2-(diethylamino)-2-oxoethyl)-N,N-diethyl-2methylfuran-3-carboxamide 3ma and N,N-dibutyl-2-(5-phenyl-4-tosylfuran-2-yl)acetamide **3nc**, respectively, in 57–72% yields (Table 2, entries 31–33).

3. Materials and Methods

3.1. General Experimental Methods

Melting points were measured with a Leitz Laborlux 12 POL polarizing optical microscope (Leitz Italia GmbH/Srl, Lana, BZ, Italy) and are uncorrected. ¹H NMR and ¹³C NMR spectra were recorded at 25 °C in CDCl₃ at 500 MHz and 125 MHz, respectively, with Me₄Si as internal standard using Bruker DPX Avance 300 and Bruker DPX Avance 500 NMR Spectrometers (Bruker Italia s.r.l., Milano, Italy); chemical shifts (δ) and coupling constants (*J*) are given in ppm and in Hz, respectively. IR spectra were taken with a JASCO FT-IR 4200 spectrometer (Jasco Europe s.r.l., Cremella, Lecco, Italy). All reactions were analyzed by TLC on silica gel 60 F₂₅₄ and by GC-MS analysis using a Shimadzu QP-2010 GC–MS apparatus (Shimadzu Italia s.r.l., Milano, Italy) at 70 eV ionization voltage equipped with a 95% methyl polysiloxane-5% phenyl polysiloxane capillary column ($30 \text{ m} \times 0.25 \text{ mm}$, 0.25 µm). Column chromatography was performed on silica gel 60 (Merck, 70–230 mesh; Merck Life Science s.r.l., Milano, Italy). Evaporation refers to the removal of solvent under reduced pressure. The HRMS spectra were taken on an Agilent 1260 Infinity UHD accurate-mass Q-TOF-MS mass spectrometer (Agilent Technologies, Santa Clara, CA, USA), equipped with an electrospray ion source (ESI) operated in dual ion mode. A total of 10 µL of the sample solutions (CH₃OH) were introduced by continuous infusion at a flow rate of 200 L min⁻¹ with the aid of a syringe pump. Experimental conditions were performed as follows: capillary voltage, 4000 V; nebulizer pressure, 20 psi; flow rate of drying gas, 10 L/min; temperature of sheath gas, 325 °C; flow rate of sheath gas, 10 L/min; skimmer voltage, 60 V; OCT1 RF Vpp, 750 V; fragmentor voltage, 170 V. The spectra data were recorded in the *m/z* range of 100–1000 Da in a centroid pattern of full-scan MS analysis mode. The MS/MS data of the selected compounds were obtained by regulating diverse collision energy (18–45 eV).

3.2. Preparation of Substrates

Substrates **1** were prepared and characterized as described in Supplementary Materials. All other materials were commercially available and were used without further purification.

3.3. General Procedure for the Synthesis of 2-(4-Acylfuran-2-yl)acetamides 3

A 35 mL stainless steel autoclave was charged in the presence of air with PdI₂ (1.2 mg, 3.3×10^{-3} mmol, or 3.6 mg, 1.0×10^{-2} mmol; see Table 1), KI (55 mg, 0.33 mmol or 166 mg, 1.0 mmol), a solution of **1** [1.0 mmol; **1a**, 138 mg; **1b**, 166 mg; **1c**, 150 mg; **1d**, 152 mg; **1e**, 262 mg; **1f**, 338 mg; **1g**, 200 mg; **1h**, 154 mg; **1i**, 168 mg; **1j**, 196 mg; **1k**, 196 mg; **1l**, 230 mg; **1m**, 195 mg; **1n**, 312 mg] in anhydrous CH₃CN (5.0 mL), and the amine **2** [4.0 mmol; **2a**, 292 mg; **2b**, 180 mg (2 mL of a 2 M solution in THF); **2c**, 516 mg; **2d**, 508 mg; **2e**, 404 mg; **2f**, 348 mg]. The autoclave was sealed and, while the mixture was stirred, the autoclave was pressurized with CO (16 atm) and air (up to 20 atm). After being stirred at 100 °C for 15 h, the autoclave was cooled, degassed, and opened. After evaporation of the solvent, products **3** were purified by column chromatography on silica gel using as eluent hexane-AcOEt from 8:2 to 6:4.

3.3.1. 2-(4-Acetyl-5-methylfuran-2-yl)-N,N-diethylacetamide (3aa)

Yield: 170 mg, starting from 138 mg of **1a** (72%) (Table 1, entry 1). Yellow oil. IR (film): v = 1667 (s), 1651 (s), 1566 (m), 1435 (m), 1404 (w), 1234 (m), 1134 (w), 949 (m), 795 (w) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 6.45$ (s, 1 H), 3.67 (s, 2 H), 3.44–3.35 (m, 4 H), 2.55 (s, 3 H), 2.37 (s, 3 H), 1.20 (t, *J* = 7.1, 3 H), 1.15 (t, *J* = 7.1, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 194.2$, 167.3, 157.7, 147.2, 122.2, 108.3, 42.5, 40.5, 33.2, 29.1, 14.34, 14.31, 12.9; GC-MS (EI): m/z = 237 (M⁺, 10), 137 (9), 100 (100), 72 (71); HRMS (ESI—TOF) m/z: [M + Na]⁺ Calcd. for C₁₃H₁₉NNaO₃⁺ 260.1257; Found 260.1256.

3.3.2. 2-(4-Acetyl-5-methylfuran-2-yl)-*N*,*N*-dimethylacetamide (**3ab**)

Yield: 140 mg, starting from 138 mg of **1a** (67%) (Table 1, entry 3). Yellow oil, IR (film): ν = 1686 (s), 1651 (s), 1557 (m), 1508 (w), 1396 (m), 1234 (m), 1138 (m), 1061 (w), 945 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 6.44 (s, 1 H), 3.69 (s, 2 H), 3.10 (s, 3 H), 2.99 (m, 3 H), 2.55 (s, 3 H), 2.37 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃): δ = 194.2, 168.3, 157.8, 146.9, 122.3, 108.4, 37.7, 35.7, 33.4, 29.1, 14.3; GC-MS (EI): m/z = 209 (M⁺, 17), 137 (22), 72 (100); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₁₁H₁₅NNaO₃⁺ 232.0944; Found 232.0948.

3.3.3. 2-(4-Acetyl-5-methylfuran-2-yl)-N,N-dibutylacetamide (3ac)

Yield: 219 mg, starting from 138 mg of **1a** (75%) (Table 1, entry 5). Yellow oil. IR (film): v = 1678 (s), 1643 (s), 1570 (m), 1454 (m), 1431 (m), 1373 (w), 1223 (m), 1138 (w), 1114 (w), 945 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 6.44$ (s, 1 H), 3.67 (s, 2 H), 3.37–3.32 (m, 2 H), 3.31–3.26 (m, 2 H), 2.55 (s, 3 H), 2.37 (s, 3 H), 1.61–1.49 (m, 4 H), 1.40–1.27 (m, 4 H), 0.96 (t, J = 7.3, 3 H), 0.92 (t, J = 7.3, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 194.2$, 167.7, 157.7, 147.3,

122.3, 108.3, 48.3, 46.1, 33.3, 33.2, 31.3, 29.8, 29.1, 20.3, 20.1, 14.4, 13.9; GC-MS (EI): m/z = 293 (M⁺, 4), 156 (38), 137 (11), 100 (27), 57 (100); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₁₇H₂₇NNaO₃⁺ 316.1883; Found 316.1898.

3.3.4. 2-(4-Acetyl-5-methylfuran-2-yl)-*N*-cyclohexyl-*N*-ethylacetamide (Mixture of Rotamers A + B, Deriving from Hindered Rotation around the Amide Bond: A/B *ca* 1.2 by ¹H NMR) (**3ad**)

Yield: 215 mg, starting from 138 mg of **1a** (74%) (Table 1, entry 7). Yellow oil. IR (film): v = 1674 (m), 1643 (s), 1570 (w), 1427 (m), 1369 (w), 1234 (m), 1103 (w), 895 (w) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 6.45$ [s, 1 H (A or B)], 6.44 [s, 1 H (B or A)], 4.31 [tt, *J* = 11.7, 3.5, 1 H (B)], 3.71 [s, 2 H (A)], 3.66 [s, 2 H (B)], 3.62 [tt, *J* = 11.7, 3.5, 1 H (A)], 3.37–3.27 [m, 2 H (A) + 2 H (B)], 2.56 [s, 3 H (A)], 2.55 [s, 3 H (B)], 2.37 [s, 3 H (A) + 3 H (B)], 1.90–1.60 [m, 4 H (A) + 4 H (B)], 1.56–1.22 [m, 6 H (A) + 6 H (B)], 1.23 [t, *J* = 7.2, 3 H (B)], 1.15 [t, *J* = 7.0, 3 H (A)]; ¹³C NMR (125 MHz, CDCl₃): $\delta = 194.1$ (A + B), 167.8 (B), 167.2 (A), 157.6 (A + B), 147.5 (A + B), 122.2 (A + B), 108.2 (A + B), 58.0 (A), 57.9 (B), 54.4 (A), 54.3 (B), 38.4 (B), 36.9 (A), 34.1 (A), 33.5 (B), 31.8 (A), 30.9 (B), 29.1 (A + B), 25.9 (A + B), 25.6 (B), 25.2 (A), 16.8 (A + B), 148.8 (A), 14.3 (B); GC-MS (EI): m/z = 291 (M⁺, 3), 154 (49), 137 (14), 123 (4), 95 (8), 83 (100); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₁₇H₂₅NNaO₃⁺ 314.1727; Found 314.1712.

3.3.5. 2-(4-Acetyl-5-methylfuran-2-yl)-*N*,*N*-diisopropylacetamide (**3ae**)

Yield: 143 mg, starting from 138 mg of **1a** (54%) (Table 1, entry 9). Yellow oil. IR (film): v = 1651 (s), 1643 (s), 1566 (m), 1454 (m), 1369 (m), 1339 (w), 1231 (w), 1211 (m), 1041 (w), 945 (w) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 6.43$ (s, 1 H), 4.03 (heptuplet, J = 6.6, 1 H), 3.66 (s, 2 H), 3.57–3.44 (m, 1 H), 2.57 (s, 3 H), 2.37 (s, 3 H), 1.40 (d, J = 6.7), 1.21 (d, J = 6.6); ¹³C NMR (125 MHz, CDCl₃): $\delta = 194.2$, 166.9, 152.6, 147.6, 122.3, 108.2, 49.3, 46.1, 35.5, 29.1, 20.9, 20.6, 20.5, 14.4, 14.3; GC-MS (EI): m/z = 265 (M⁺, 2), 137 (19), 128 (53), 96 (7), 86 (94), 43 (100); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₁₅H₂₃NNaO₃⁺ 288.1570; Found 288.1561.

3.3.6. 2-(4-Acetyl-5-methylfuran-2-yl)-1-morpholinoethan-1-one (**3af**)

Yield: 186 mg, starting from 138 mg of **1a** (74%) (Table 1, entry 10). Yellow oil. IR (film): $\nu = 1667$ (s), 1651 (s), 1566 (m), 1435 (m), 1366 (w), 1273 (w), 1227 (m), 1111 (m), 1042 (w), 964 (w), 772 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 6.45$ (s, 1 H), 3.74–3.62 (m, 6 H), 3.70 (s, 2 H), 3.57–3.53 (m, 2 H), 2.56 (s, 3 H), 2.38 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 194.0$, 166.8, 157.8, 146.5, 122.3, 108.5, 66.7, 66.5, 46.6, 42.3, 33.1, 29.1, 14.3; GC-MS (EI): m/z = 251 (M⁺, 20), 137 (33), 114 (100), 70 (76); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₁₃H₁₇NNaO₄⁺ 274.1050; Found 274.1050.

3.3.7. *N*,*N*-Diethyl-2-(5-ethyl-4-propionylfuran-2-yl)acetamide (3ba)

Yield: 214 mg, starting from 166 mg of **1b** (81%) (Table 1, entry 12). Colorless oil. IR (film): v = 1674 (s), 1647 (s), 1562 (m), 1458 (m), 1431 (w), 1254 (w), 1219 (m), 1134 (w), 1011 (w), 926 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 6.45$ (s, br, 1 H), 3.68 (d, J = 0.7, 2 H), 3.42 (q, J = 7.1, 2 H), 3.39 (q, J = 7.1, 2 H), 2.99 (q, J = 7.5, 2 H), 2.72 (q, J = 7.3, 2 H), 1.22 (t, J = 7.5, 3 H), 1.19 (t, J = 7.1, 3 H), 1.15 (t, J = 7.1, 3 H), 1.13 (t, J = 7.3, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 197.2, 167.4, 162.5, 147.1, 120.8, 107.8, 42.5, 40.5, 34.4, 33.4, 21.6, 14.3, 12.9,$ 12.1, 7.9; GC-MS (EI): <math>m/z = 265 (M⁺, 16), 165 (5), 100 (100), 72 (47); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₁₅H₂₃NNaO₃⁺ 288.1570; Found 288.1576.

3.3.8. *N*,*N*-Diethyl-2-(4-oxo-4,5,6,7-tetrahydrobenzofuran-2-yl)acetamide (3ca)

Yield: 167 mg, starting from 150 mg of **1c** (67%) (Table 1, entry 14). Yellow oil. IR (film): v = 1682 (s), 1667 (s), 1582 (w), 1442 (m), 1366 (w), 1219 (m), 1111 (m), 1003 (m), 772 (w) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 6.44$ (s, 1 H), 3.70 (s, 2 H), 3.43–3.33 (m, 4 H), 2.86 (t, *J* = 6.3, 2 H), 2.47 (t, *J* = 6.3, 2 H), 2.16 (quintuplet, *J* = 6.3, 2 H), 1.20 (t, *J* = 7.1, 3 H), 1.14 (t, *J* = 7.1, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 194.4$, 167.1, 166.8, 149.9, 122.1,

104.3, 42.5, 40.5, 37.6, 33.5, 23.4, 22.6, 14.3, 12.9; GC-MS (EI): m/z = 249 (M⁺, 10), 149 (6), 100 (100), 72 (50); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₁₄H₁₉NNaO₃⁺ 272.1257; Found 272.1261.

3.3.9. 2-(4-Acetyl-3,5-dimethylfuran-2-yl)-1-morpholinoethan-1-one (3df)

Yield: 175 mg, starting from 152 mg of **1d** (66%) (Table 1, entry 16). Yellow solid, mp 90–91 °C. IR (film): v = 1655 (s), 1558 (w), 1416 (m), 1354 (w), 1304 (w), 1231 (m), 1115 (m), 1072 (w), 1034 (w), 972 (m), 848 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 3.69-3.62$ (m, 6 H), 3.63 (s, 2 H), 3.57–3.53 (m, 2 H), 2.53 (s, 3 H), 2.42 (s, 3 H), 2.16 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 194.8$, 167.1, 157.3, 142.8, 123.3, 117.2, 66.8, 66.6, 46.5, 42.4, 31.3, 30.9, 15.3, 10.6; GC-MS (EI): m/z = 265 (M⁺, 26), 222 (3), 151 (100), 133 (6), 114 (40), 70 (30); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₁₄H₁₉NNaO₄⁺ 288.1206; Found 288.1216.

3.3.10. 2-(4-Benzoyl-5-phenylfuran-2-yl)-N,N-diethylacetamide (3ea)

Yield: 245 mg, starting from 262 mg of **1e** (68%) (Table 1, entry 17). Colorless oil. IR (film): v = 1647 (s), 1551 (w), 1485 (m), 1447 (m), 1381 (w), 1261 (m), 1227 (m), 1134 (w), 1072 (w), 887 (m), 729 (m), 694 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 7.86-7.80$ (m, 2 H), 7.68–7.63 (m, 2 H), 7.51–7.45 (m, 1 H), 7.38–7.33 (m, 2 H), 7.30–7.23 (m, 3 H), 6.53 (t, br, 1 H), 3.81 (d, J = 0.7, 2 H), 3.46–3.38 (m, 4 H), 1.22 (t, J = 7.1.3 H), 1.16 (t, J = 7.1, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 191.7, 167.1, 155.3, 148.5, 138.1, 132.8, 129.7, 128.9, 128.3, 127.7, 127.5, 121.9, 111.6, 42.6, 40.6, 33.6, 14.5, 13.0; GC-MS (EI): <math>m/z = 361$ (M⁺, 17), 261 (14), 105 (21), 100 (100), 77 (18); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₂₃H₂₃NNaO₃⁺ 384.1570; Found 384.1580.

3.3.11. 2-(4-Benzoyl-3,5-diphenylfuran-2-yl)-*N*,*N*-diethylacetamide (3fa)

Yield: 235 mg, starting from 338 mg of **1f** (54%) (Table **1**, entry 19). Colorless oil. IR (film): v = 1647 (s), 1597 (w), 1489 (w), 1447 (m), 1381 (w), 1335 (w), 1254 (m), 1126 (w), 1077 (w), 899 (m), 733 (m), 694 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 7.85-7.77$ (m, 2 H), 7.62–7.56 (m, 2 H), 7.41–7.10 (m, 11 H), 3.80 (s, 2 H), 3.46 (q, J = 7.1, 2 H), 3.35 (q, J = 7.1, 2 H), 1.18 (t, J = 7.1, 3 H), 1.15 (t, J = 7.1, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 193.6, 167.6, 151.9, 145.5, 137.3, 133.3, 131.6, 129.90, 129.71, 129.3, 128.43, 128.36, 128.25, 127.4, 126.5, 125.7, 121.8, 42.4, 40.7, 32.1, 14.3, 13.1; GC-MS (EI): <math>m/z = 437$ (M⁺, 40), 337 (67), 259 (2), 202 (3), 105 (100), 100 (77), 72 (31); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₂₉H₂₇NNaO₃⁺ 460.1883; Found 460.1901.

3.3.12. 2-(4-Benzoyl-5-methylfuran-2-yl)-1-morpholinoethan-1-one (3gf)

Yield: 150 mg, starting from 200 mg of **1g** (48%) (Table 1, entry 20). Colorless oil. IR (film): v = 1647 (s), 1566 (m), 1447 (m), 1273 (w), 1231 (m), 1115 (m), 1038 (w), 903 (m), 729 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 7.81-7.75$ (m, 2 H), 7.58–7.52 (m, 1 H), 7.49–7.43 (m, 2 H), 6.41 (s, 1 H), 3.72 (s, 2 H), 3.71–3.63 (m, 6 H), 3.57–3.53 (m, 2 H), 2.50 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 191.1$, 166.8, 159.0, 146.4, 139.1, 132.2, 128.9, 128.4, 121.4, 109.9, 66.8, 66.6, 46.7, 42.4, 33.3, 14.2; GC-MS (EI): m/z = 313 (M⁺, 35), 270 (2), 199 (42), 114 (100), 105 (11), 70 (55); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₁₈H₁₉NNaO₄⁺ 336.1206; Found 336.1209.

3.3.13. 2-(4-Acetyl-5-phenylfuran-2-yl)-1-morpholinoethan-1-one (3gf')

Yield: 78 mg, starting from 200 mg of **1g** (25%) (Table 1, entry 20). Colorless oil. IR (film): v = 1651 (s), 1543 (w), 1447 (m), 1381 (w), 1273 (w), 1234 (m), 1115 (s) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 7.87-7.80$ (m, 2 H), 7.48–7.40 (m, 3 H), 6.64 (t, br, J = 0.7, 1 H), 3.80 (d, J = 0.7, 2 H), 3.73–3.64 (m, 6 H), 3.60–3.56 (m, 2 H), 2.38 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 193.8, 166.6, 156.1, 147.8, 129.8, 129.7, 128.5, 128.3, 123.2, 110.5, 66.8, 66.6, 46.7, 42.4, 33.3, 29.8; GC-MS (EI): <math>m/z = 313$ (M⁺, 45), 199 (100), 181 (6), 157 (5), 128 (14), 114 (98), 105 (13), 70 (61); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₁₈H₁₉NNaO₄⁺ 336.1206; Found 336.1217.

3.3.14. Methyl 5-(2-(Diethylamino)-2-oxoethyl)-2-methylfuran-3-carboxylate (3ha)

Yield: 177 mg, starting from 154 mg of **1h** (70%) (Table 1, entry 21). Yellow oil. IR (film): $\nu = 1713$ (s), 1651 (s), 1582 (w), 1451 (m), 1396 (w), 1219 (m), 1088 (m), 995 (w), 779 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 6.43$ (s, 1 H), 3.79 (s, 3 H), 3.65 (s, 2 H), 3.40 (q, *J* = 7.1, 2 H), 3.36 (q, *J* = 7.1, 2 H), 2.54 (s, 3 H), 1.18 (t, *J* = 7.1), 1.14 (t, *J* = 7.1, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 167.3$, 164.5, 158.7, 147.3, 114.1, 108.4, 51.2, 42.5, 40.5, 33.5, 14.3, 13.7, 12.9; GC-MS (EI): m/z = 253 (M⁺, 9), 222 (5), 153 (4), 121 (12), 100 (100), 72 (55); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₁₃H₁₉NNaO₄⁺ 276.1206; Found 276.1218.

3.3.15. Ethyl 5-(2-(Diethylamino)-2-oxoethyl)-2-methylfuran-3-carboxylate (3ia)

Yield: 184 mg, starting from 168 mg of **1i** (69%) (Table 1, entry 23). Colorless oil. IR (film): v = 1713 (s), 1647 (s), 1578 (w), 1466 (m), 1381 (m), 1215 (s), 1099 (w), 1061 (m), 783 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 6.43$ (s, 1 H), 4.26 (q, *J* = 7.1), 3.64 (s, 2 H), 3.45–3.32 (m, 4 H), 2.53 (s, 3 H), 1.32 (t, *J* = 7.1. 3 H), 1.18 (t, *J* = 7.1, 3 H), 1.14 (t, *J* = 7.1, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 167.4$, 164.1, 158.4, 147.3, 114.6, 108.5, 60.0, 42.5, 40.5, 33.5, 14.38, 14.36, 13.7, 12.9; GC-MS (EI): m/z = 267 (M⁺, 30), 222 (23), 167 (10), 139 (10), 121 (22), 100 (100), 72 (99); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₁₄H₂₁NNaO₄⁺ 290.1363; Found 290.1368.

3.3.16. Ethyl 5-(2-(Diethylamino)-2-oxoethyl)-2-propylfuran-3-carboxylate (3ja)

Yield: 200 mg, starting from 196 mg of **1j** (68%) (Table 1, entry 25). Colorless oil. IR (film): v = 1713 (s), 1647 (s), 1578 (w), 1462 (m), 1431 (m), 1381 (w), 1215 (m), 1096 (m), 1050 (m), 779 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 6.45$ (s, br, 1 H), 4.26 (q, *J* = 7.1, 2 H), 3.66 (d, *J* = 0.6, 2 H), 3.42–3.34 (m, 4 H), 2.93 (t, *J* = 7.4, 2 H), 1.68 (sextuplet, *J* = 7.4, 2 H), 1.32 (t, *J* = 7.1, 3 H), 1.17 (t, *J* = 7.1, 3 H), 1.13 (t, *J* = 7.1, 3 H), 0.94 (t, *J* = 7.4, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 167.3$, 164.0, 162.4, 147.2, 114.2, 108.3, 60.0, 42.5, 40.4, 33.6, 29.5, 21.6, 14.3, 13.8, 13.7, 12.9; GC-MS (EI): *m*/*z* = 295 (M⁺, 6), 250 (3), 195 (3), 100 (100), 72 (37); HRMS (ESI-TOF) *m*/*z*: [M + Na]⁺ Calcd. for C₁₆H₂₅NNaO₄⁺ 318.1676; Found 318.1683.

3.3.17. Ethyl 5-(2-(Diethylamino)-2-oxoethyl)-2-isopropylfuran-3-carboxylate (3ka)

Yield: 209 mg, starting from 196 mg of **1k** (71%) (Table 1, entry 27). Colorless oil. IR (film): $\nu = 1713$ (s), 1647 (s), 1578 (w), 1381 (m), 1458 (m), 1365 (w), 1215 (m), 1130 (w), 1099 (w), 1061 (m), 783 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 6.44$ (s, 1 H), 4.26 (q, *J* = 7.1, 2 H), 3.73 (heptuplet, *J* = 7.0, 1 H), 3.67 (s, 2H), 3.45–3.35 (m, 4 H), 1.32 (t, *J* = 7.1. 3 H), 1.25 (d, *J* = 7.0, 6 H), 1.17 (t, *J* = 7.1, 3 H), 1.14 (t, *J* = 7.1, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 167.3$, 166.4, 164.0, 146.9, 112.5, 108.2, 59.9, 42.5, 40.4, 33.7, 27.2, 20.78, 20.75, 14.3, 12.9; GC-MS (EI): *m*/*z* = 295 (M⁺, 7), 250 (4), 195 (3), 125 (2), 100 (100), 72 (38); HRMS (ESI-TOF) *m*/*z*: [M + Na]⁺ Calcd. for C₁₆H₂₅NNaO₄⁺ 318.1676; Found 318.1675.

3.3.18. Benzyl 5-(2-(Diethylamino)-2-oxoethyl)-2-methylfuran-3-carboxylate (3la)

Yield: 220 mg, starting from 230 mg of **11** (67%) (Table 1, entry 29). Colorless oil. IR (film): v = 1713 (s), 1647 (s), 1585 (w), 1454 (m), 1431 (m), 1381 (w), 1365 (w), 1219 (m), 1076 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 7.41-7.29$ (m, 5 H), 6.47 (s, 1 H), 5.25 (s, 2 H), 3.64 (s, 2 H), 3.39 (q, *J* = 7.1, 2 H), 3.35 (q, *J* = 7.1, 2 H), 2.55 (s, 3 H), 1.17 (t, *J* = 7.1, 3 H), 1.13 (t, *J* = 7.1, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 167.4$, 163.9, 159.0, 147.4, 136.4, 128.6, 128.2, 128.1, 114.2, 108.6, 65.9, 42.5, 40.5, 33.5, 14.4, 14.0, 13.0; GC-MS (EI): *m*/*z* = 329 (M⁺, 5), 212 (6), 194 (2), 100 (100), 91 (18), 72 (35); HRMS (ESI-TOF) *m*/*z*: [M + Na]⁺ Calcd. for C₁₉H₂₃NNaO₄⁺ 352.1519; Found 352.1543.

3.3.19. 5-(2-(Diethylamino)-2-oxoethyl)-N,N-diethyl-2-methylfuran-3-carboxamide (3ma)

Yield: 168 mg, starting from 195 mg of **1m** (57%) (Table 1, entry 31). Colorless oil, IR (film): $\nu = 1632$ (s), 1454 (m), 1381 (w), 1362 (w), 1269 (w), 1072 (w), cm⁻¹; ¹H NMR (300 MHz, CDCl₃): $\delta = 6.13$ (s, 1 H), 3.66 (s, 2 H), 3.48–3.32 (m, 8 H), 2.34 (s, 3 H), 1.23–1.10 (m, 12 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 167.5$, 165.8, 152.0, 146.9, 117.4, 107.4, 42.5,

40.3, 39.2, 33.7, 14.3, 12.9; GC-MS (EI): m/z = 294 (M⁺, 10), 222 (5), 194 (6), 152 (7), 123 (12), 100 (100), 72 (56); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₁₆H₂₆N₂NaO₃⁺ 317.1836; Found 317.1837.

3.3.20. N,N-Dibutyl-2-(5-phenyl-4-tosylfuran-2-yl)acetamide (3nc)

Yield: 336 mg, starting from 312 mg of **1n** (72%) (Table 1, entry 32). Yellow oil. IR (film): v = 1643 (s), 1597 (w), 1551 (w), 1485 (m), 1454 (m), 1319 (s), 1254 (w), 1215 (w), 1153 (s), 1103 (m), 930 (w), 814 (w), 698 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): $\delta = 7.85-7.81$ (m, 2 H), 7.69–7.65 (m, 2 H), 7.42–7.38 (m, 3 H), 7.20–7.16 (m, 2 H), 6.64 (t, *J* = 0.8, 1 H), 3.73 (d, *J* = 0.8, 2 H), 3.36–3.31 (m, 2 H), 3.28–3.24 (m, 2 H), 2.35 (s, 3 H), 1.59–1.48 (m, 4 H), 1.36–1.22 (m, 4 H), 0.93 (t, *J* = 7.4, 3 H), 0.91 (t, *J* = 7.4, 3 H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 166.8$, 154.1, 148.9, 144.1, 139.0, 129.8, 129.6, 128.7, 128.4, 128.2, 127.2, 110.3, 48.3, 46.1, 33.4, 31.3, 29.7, 21.5, 20.2, 20.1, 13.8; GC-MS (EI): m/z = 467 (M⁺, 10), 311 (9), 253 (2), 207 (8), 156 (100), 128 (11), 100 (39), 57 (68); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd. for C₂₇H₃₃NNaO₄S⁺ 490.2023; Found 490.2037.

3.4. Synthesis of 2-(4-Benzoyl-5-phenylfuran-2-yl)-N,N-diethylacetamide (3ea) in Larger Scale

A 250 mL stainless steel autoclave was charged in the presence of air with PdI₂ (8.6 mg, 2.4×10^{-2} mmol), KI (398 mg, 2.4 mmol), a solution of 1,3-diphenyl-2-(prop-2-yn-1-yl)propane-1,3-dione **1e** (627 mg, 2.4 mmol) in anhydrous CH₃CN (12 mL), and diethylamine **2a** (700 mg, 9.6 mmol). The autoclave was sealed and, while the mixture was stirred, the autoclave was pressurized with CO (16 atm) and air (up to 20 atm). After being stirred at 100 °C for 15 h, the autoclave was cooled, degassed, and opened. After evaporation of the solvent, product **3ea** were purified by column chromatography on silica gel using as eluent hexane-AcOEt from 8:2 to 6:4 (yield: 586 mg, 68%).

4. Conclusions

In conclusion, we have reported the synthesis of a previously unreported subclass of furan derivatives (2-(4-acylfuran-2-yl)acetamides) by a direct catalytic carbonylative approach starting from readily available building blocks (2-propargyl-1,3-dicarbonyl compounds, secondary amines, and oxygen). The process is catalyzed by the simple PdI_2/KI catalytic system and takes place through an ordered sequence of steps, involving: PdI_2/KI catalyzed oxidative monaminocarbonylation of the terminal triple bond of the substrate to give the corresponding 2-ynamide intermediate; base-induced enolization and 5-*exo-dig O*-cyclization via intramolecular conjugate addition to the 2-ynamide moiety; double bond shift with aromative isomerization.

Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/molecules28196764/s1, Preparation and characterization of substrates, Copies of HRMS, ¹H NMR, and ¹³C NMR spectra for substrates **1b**, **1d**, **1k**, **1m** and products **3aa**, **3ab**, **3ac**, **3ad**, **3ae**, **3af**, **3ba**, **3ca**, **3df**, **3ea**, **3fa**, **3gf**, **3gf**', **3ha**, **3ia**, **3ja**, **3ka**, **3la**, **3ma**, **3nc**. References [33–41] are cited in Supplementary Materials.

Author Contributions: Conceptualization: B.G. and L.V.; methodology: I.Z., L.V., T.P., R.A., M.A.C., R.M. and B.G.; validation: I.Z., L.V., T.P., R.A., M.A.C. and R.M.; investigation: I.Z., L.V., T.P., R.A., M.A.C. and R.M.; writing—original draft preparation: B.G.; writing—review and editing: B.G.; supervision: B.G. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding authors.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds 3aa, 3ab, 3ac, 3ad, 3ae, 3af, 3ba, 3ca, 3df, 3ea, 3fa, 3gf, 3gf', 3ha, 3ia, 3ja, 3ka, 3la, 3ma, and 3nc are available from the authors.

References

- 1. Furan Derivatives: Recent Advances and Applications; Khan, A.; Rahman, M.M.; Ramesh, M.; Khan, S.; Asiri, A.M. (Eds.) IntechOpen: London, UK, 2022.
- 2. Alizadeh, M.; Jalal, M.; Hamed, K.; Saber, A.; Kheirouri, S.; Tabrizi, F.P.F.; Kamari, N. Recent Updates on Anti-Inflammatory and Antimicrobial Effects of Furan Natural Derivatives. *J. Inflamm. Res.* **2020**, *13*, 451–463. [CrossRef]
- 3. Sperry, J.B.; Wright, D.L. Furans, Thiophenes and Related Heterocycles in Drug Discovery. *Curr. Opin. Drug Discov. Dev.* 2005, *8*, 723–740. [CrossRef]
- 4. Zhang, B.; Huo, L.J. Recent Advances of Furan and Its Derivatives Based Semiconductor Materials for Organic Photovoltaics. *Small Methods* **2021**, *5*, 2100493. [CrossRef]
- Deepthi, A.; Babu, B.P.; Balachandran, A.L. Synthesis of Furans—Recent Advances. Org. Prep. Proced. Int. 2019, 51, 409–442. [CrossRef]
- Zhang, W.; Xu, W.; Zhang, F.; Li, Y. Recent Progress in Synthesis of Polysubstituted Furans. *Chin. J. Org. Chem.* 2019, 39, 1277–1283. [CrossRef]
- 7. Duc, D.X. Recent Progress in the Synthesis of Furan. Mini-Rev. Org. Chem. 2019, 16, 422–452. [CrossRef]
- 8. Nejrotti, S.; Prandi, C. Gold Catalysis and Furans: A Powerful Match for Synthetic Connections. *Synthesis* **2021**, *53*, 1046–1060. [CrossRef]
- Wang, Y.; Zhang, C.; Li, S. Progress in Cyclizations of 4-Acetylenic Ketones: Synthesis of Furans and Pyrroles. *ChemistrySelect* 2020, 5, 8656–8668. [CrossRef]
- 10. Wu, X.-F. Transition Metal Catalyzed Furans Synthesis; Elsevier: Amsterdam, The Netherlands, 2015.
- 11. Pandey, S.; Shukla, R.K.; Volla, C.M.R. Access to Polysubstituted Furan Derivatives via Cascade Oxypalladation and Hydrocarbofunctionalization of Unactivated Alkenes. *Org. Lett.* **2023**, *25*, 4694–4699. [CrossRef]
- 12. Carbon Monoxide in Organic Synthesis: Carbonylation Chemistry; Gabriele, B. (Ed.) Wiley-VCH: Weinheim, Germany, 2021; ISBN 978-3527347957.
- Gabriele, B. Chapter 3—Synthesis of Heterocycles by Palladium-Catalyzed Carbonylative Reactions. In Advances in Transition-Metal Mediated Heterocyclic Synthesis; Solé, D., Fernández, I., Eds.; Academic Press-Elsevier: London, UK, 2018; pp. 55–127.
- 14. Feng, J.-B.; Wu, X.-F. Palladium-Catalyzed Synthesis of Heterocycles. In *Advances in Heterocyclic Chemistry*; Scriven, E.F.V., Ramsden, C.A., Eds.; Academic Press: Cambridge, MA, USA, 2017; Volume 121, pp. 207–246.
- 15. *Transition Metal Catalyzed Carbonylative Synthesis of Heterocycles*; Wu, X.-F.; Beller, M. (Eds.) Topics in Heterocyclic Chemistry; Springer: Cham, Switzerland, 2016; Volume 42.
- 16. Yin, Z.; Xu, J.; Wu, X.-F. No Making without Breaking: Nitrogen-Centered Carbonylation Reactions. ACS Catal. 2020, 10, 6510–6531. [CrossRef]
- 17. Peng, J.-B.; Wu, F.-P.; Wu, X.-F. First-row Transition-Metal-Catalyzed Carbonylative Transformations of Carbon Electrophiles. *Chem. Rev.* 2019, *119*, 2090–2127. [CrossRef]
- Ma, K.; Martin, B.S.; Yin, X.; Dai, M. Natural Product Syntheses via Carbonylative Cyclizations. *Nat. Prod. Rep.* 2019, 36, 174–219. [CrossRef]
- 19. Perrone, S.; Troisi, L.; Salomone, A. Heterocycle Synthesis through Pd-Catalyzed Carbonylative Coupling. *Eur. J. Org. Chem.* 2019, 2019, 4626–4643. [CrossRef]
- Albano, G.; Aronica, L.A. Potentiality and Synthesis of O- and N-Heterocycles: Pd-Catalyzed Cyclocarbonylative Sonogashira Coupling as a Valuable Route to Phthalans, Isochromans, and Isoindolines. *Eur. J. Org. Chem.* 2017, 2017, 7204–7221. [CrossRef]
- 21. Shen, C.R.; Wu, X.-F. Palladium-Catalyzed Carbonylative Multicomponent Reactions. Chem. Eur. J. 2017, 23, 2973–2987. [CrossRef]
- 22. Wu, X.-F.; Neumann, H.; Beller, M. Synthesis of Heterocycles via Palladium-Catalyzed Carbonylations. *Chem. Rev.* 2013, 113, 1–35. [CrossRef]
- 23. Gabriele, B.; Mancuso, R.; Salerno, G. Oxidative Carbonylation as a Powerful Tool for the Direct Synthesis of Carbonylated Heterocycles. *Eur. J. Org. Chem.* **2012**, 2012, 6825–6839. [CrossRef]
- 24. Gabriele, B.; Costa, M.; Salerno, G.; Chiusoli, G.P. A New Synthesis of Trimethyl Aconitate by Palladium-Catalysed Triple Carbonylation of Propynyl Alcohol. *J. Chem. Soc. Chem. Commun.* **1992**, 1992, 1007–1008. [CrossRef]
- 25. Gabriele, B.; Costa, M.; Salerno, G.; Chiusoli, G.P. An Efficient and Selective Palladium-Catalysed Oxidative Dicarbonylation of Alkynes to Alkyl- or Aryl-maleic Esters. *J. Chem. Soc. Perkin Trans.* **1994**, *1*, 83–87. [CrossRef]
- Mancuso, R.; Della Ca', N.; Veltri, L.; Ziccarelli, I.; Gabriele, B. PdI₂-Based Catalysis for Carbonylation Reactions: A Personal Account. *Catalysts* 2019, 9, 610. [CrossRef]
- 27. Gabriele, B.; Salerno, G.; Veltri, L.; Costa, M. Synthesis of 2-Ynamides by Direct Palladium-Catalyzed Oxidative Aminocarbonylation of Alk-1-ynes. J. Organomet. Chem. 2001, 622, 84–88. [CrossRef]
- Ziccarelli, I.; Mancuso, R.; Giacalone, F.; Calabrese, C.; La Parola, V.; De Salvo, A.; Della Ca', N.; Gruttadauria, M.; Gabriele, B. Heterogenizing Palladium Tetraiodide Catalyst for Carbonylation Reactions. *J. Catal.* 2022, 413, 1098–1110. [CrossRef]

- Veltri, L.; Amuso, R.; Prestia, T.; Vitale, P.; Gabriele, B. A Multicomponent Approach to Imidazo[2,1-b]thiazole Derivatives by Sequential PdI₂/KI-Catalyzed Deprotective Oxidative Aminocarbonylation—Dearomative Cyclization—Aromatization. *Eur. J.* Org. Chem. 2022, 2022, e202200916. [CrossRef]
- Gabriele, B.; Salerno, G.; Mancuso, R.; Costa, M. Efficient Synthesis of Ureas by Direct Palladium-Catalyzed Oxidative Carbonylation of Amines. J. Org. Chem. 2004, 69, 4741–4750. [CrossRef]
- 31. Mancuso, R.; Della Ca', N.; Fini, F.; Carfagna, C.; Gabriele, B. Catalytic Oxidative Carbonylation of Amino Moieties to Ureas, Oxamides, 2-Oxazolidinones, and Benzoxazolones. *ChemSusChem* **2015**, *8*, 2204–2211. [CrossRef]
- Pickersgill, F.; Marchington, A.P.; Rayner, C.M. Selective Alkylation of β-Ketoester Enolates Using O-Methyl Aminosulfoxonium Salts; the First Example of C-alkylation Using Sulfoxonium Salt Electrophiles. J. Chem. Soc. Chem. Commun. 1994, 1994, 2597–2598.
 [CrossRef]
- Misztalewska, I.; Wilczewska, A.Z.; Wojtasik, O.K.; Markiewicz, H.; Kuchlewski, P.; Majcher, A.M. New Acetylacetone-Polymer Modified Nanoparticles as Magnetically Separable Complexing Agents. *RSC Adv.* 2015, *5*, 100281–100289. [CrossRef]
- Chang, M.-Y.; Cheng, Y.-C.; Lu, W.-J. Bi(OTf)₃-Mediated Cycloisomerization of γ-Alkynyl Arylketones: Application to the Synthesis of Substituted Furans. Org. Lett. 2015, 17, 1264–1267. [CrossRef]
- Schneider, L.M.; Schmiedel, V.M.; Pecchioli, T.; Lentz, D.; Merten, C.; Christmann, M. Asymmetric Synthesis of Carbocyclic Propellanes. Org. Lett. 2017, 19, 2310–2313. [CrossRef]
- 36. Gree, R.; Park, H.; Paquette, L.A. Regio- and Stereoselective 1,2 Wagner-Meerwein Shifts during Trifluoroacetic acid Catalyzed Isomerization of Unsymmetrically Substituted Tricyclo[3.2.0.02,4]heptanes. J. Am. Chem. Soc. **1980**, 102, 4397–4403. [CrossRef]
- Sanz, R.; Miguel, D.; Martínez, A.; Álvarez-Gutiérrez, J.M.; Rodriguez, F. Brønsted Acid Catalyzed Propargylation of 1,3-Dicarbonyl Derivatives. Synthesis of Tetrasubstituted Furans. Org. Lett. 2007, 9, 727–730. [CrossRef] [PubMed]
- Ruengsangtongkul, S.; Chaisan, N.; Thongsornkleeb, C.; Tummatorn, J.; Ruchirawat, S. Rate Enhancement in CAN-Promoted Pd(PPh₃)₂Cl₂-Catalyzed Oxidative Cyclization: Synthesis of 2-Ketofuran-4-carboxylate Esters. *Org. Lett.* 2019, *21*, 2514–2517. [CrossRef] [PubMed]
- Li, W.; Wang, J.; Hu, X.; Shen, K.; Wang, W.; Chu, Y.; Lin, L.; Liu, X.; Feng, X. Catalytic Asymmetric Roskamp Reaction of α-Alkyl-α-diazoesters with Aromatic Aldehydes: Highly Enantioselective Synthesis of α-Alkyl-β-keto Esters. *J. Am. Chem. Soc.* 2010, 132, 8532–8533. [CrossRef]
- 40. Barabe, F.; Levesque, P.; Korobkov, I.; Barriault, L. Synthesis of Fused Carbocycles via a Selective 6-Endo Dig Gold(I)-Catalyzed Carbocyclization. *Org. Lett.* 2011, *13*, 5580–5583. [CrossRef]
- Katrun, P.; Songsichan, T.; Soorukram, D.; Pohmakotr, M.; Reutrakul, V.; Kuhakarn, C. o-Iodoxybenzoic Acid (IBX)–Iodine Mediated One-Pot Deacylative Sulfonylation of 1,3-Dicarbonyl Compounds: A Synthesis of β-Carbonyl Sulfones. *Synthesis* 2017, 49, 1109–1121.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.